Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development
Authors:
Open Access
- 20 July 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 1372
Abstract
The four serotypes of dengue virus (DENV) are the leading cause of arboviral diseases in humans. Decades of efforts have made remarkable progress in dengue vaccine development. Despite the first dengue vaccine (dengvaxia from Sanofi Pasteur), a live-attenuated tetravalent chimeric yellow fever-dengue vaccine, has been licensed by several countries since 2016, its overall moderate efficacy (56.5−60.8%) in the presence of neutralizing antibodies during the Phase 2b and 3 trials, lower efficacy among dengue naïve compared with dengue experienced individuals, and increased risk of hospitalization among young children during the follow-up highlight the need for a better understanding of humoral responses after natural DENV infection. Recent studies of more than 300 human monoclonal antibodies (mAbs) against DENV have led to the discovery of several novel epitopes on the envelope protein recognized by potent neutralizing mAbs. This information together with in-depth studies on polyclonal sera and B-cells following natural DENV infection has tremendous implications for better immunogen design for a safe and effective dengue vaccine. This review outlines the progress in our understanding of mouse mAbs, human mAbs and polyclonal sera against DENV envelope and precursor membrane proteins, two surface proteins involved in vaccine development, following natural infection; analyses of these discoveries have provided valuable insight into new strategies involving molecular technology to induce more potent neutralizing antibodies and less enhancing antibodies for next-generation dengue vaccine development.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI110769-01)
- National Institute of General Medical Sciences (P20GM103516)
This publication has 132 references indexed in Scilit:
- The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope ProteinPLOS Pathogens, 2013
- Structural insights into the neutralization mechanism of a higher primate antibody against dengue virusThe EMBO Journal, 2011
- The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing ActivityCell Host & Microbe, 2010
- Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue DiseaseCell Host & Microbe, 2010
- Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibodyVirology, 2009
- Structural basis for the preferential recognition of immature flaviviruses by a fusion‐loop antibodyThe EMBO Journal, 2009
- Closing the door on flaviviruses: Entry as a target for antiviral drug designAntiviral Research, 2008
- Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine DevelopmentCell Host & Microbe, 2008
- Structural proteomics of dengue virusCurrent Opinion in Microbiology, 2008
- The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus InfectionCell Host & Microbe, 2007